Varian And Antigen Effects Propel Siemens Healthineers To New Heights In FY21
Executive Summary
Siemens Healthineers became only the fifth medtech to exceed $20bn annual revenues when it reported FY21 results, a performance that included exceptional elements and positive core IVD business developments.
You may also be interested in...
Minute Insight: Siemens Healthineers Launches The World's First Photon-Counting CT Scanner
Naeotom Alpha will allow for faster, more precise, and safer computed tomography imaging for cardiac imaging, oncology, and pulmonology.
No MRA Means Switzerland’s Seamless IVDs Trade With The EU Is At An End
The EU’s full implementation of the In Vitro Diagnostic Regulation on 26 May has put the Swiss IVD industry on a "third country" footing with the EU, as happened in 2021 for medical devices. The two parties’ mutual recognition agreement for all medtech products has ceased to apply. A renewed MRA is not likely for several years.
CEO Snapshots From The MedTech Forum
Among the highlights of MedTech Europe’s annual MedTech Forum are the “unfiltered” views offered by company CEOs on the entire range of issues that influence decision-making or will have an impact on business operations in the near term.